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in cerulein pancreatitis. In taurocholate pancreatitis, glycine 
additionally diminished pancreatic cytokines and MPO ac-
tivity, as well as serum lipase and amylase levels.  Conclu-
sions: Glycine reduced the severity of mild and much more 
of severe AP by attenuating the intrapancreatic and system-
ic inflammatory response. Therefore, glycine seems to be a 
promising tool for prophylactic treatment of AP. 
 Copyright © 2011 S. Karger AG, Basel and IAP 
 Introduction 
 Acute pancreatitis is characterized by an ‘enigmatic’ 
clinical course and a very complex pathophysiology. Al-
though the course of the disease is mild in the majority 
of patients, about 25% of them suffer a severe attack. Un-
fortunately, up to 50% of the severe cases are lethal due to 
multiple organ dysfunction and/or sepsis  [1] .
 Efforts to elucidate the pathophysiology behind this 
unpredictable disease expanded our understanding of 
the nature of the disease considerably; however, there is 
still no consensus over a single a pathomechanism sug-
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 Abstract 
 Background/Aims: Acute pancreatitis (AP) is characterized 
by premature zymogen activation, systemic inflammatory 
response resulting in inflammatory infiltrates, sustained in-
tracellular calcium, neurogenic inflammation and pain. The 
inhibitory neurotransmitter and cytoprotective amino acid 
glycine exerts a direct inhibitory effect on inflammatory 
cells, inhibits calcium influx and neuronal activation and 
therefore represents a putative therapeutic agent in AP. 
 Methods: To explore the impact of glycine, mild AP was in-
duced in rats by supramaximal cerulein stimulation (10   g/
kg BW/h) and severe AP by retrograde injection of sodium 
taurocholate solution (3%) into the common biliopancreatic 
duct. 100/300 mmol glycine was administered intravenously 
before induction of AP. To elucidate the effect of glycine on 
AP, we determined pathomorphology, pancreatic cytokines 
as well as proteases, serum lipase and amylase, pancreatic 
and lung MPO activity and pain sensation.  Results: Glycine 
administration resulted in a noticeable improvement of 
pathomorphological alterations in AP, such as a reduction of 
necrosis, inflammatory infiltrates and cytoplasmic vacuoles 
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gesting that therapeutic double hits might be desirable. It 
is known that bile acids or nonoxidative alcohol metabo-
lites can trigger a sustained abnormal cytosolic ionized 
calcium (Ca 2+ ) signaling. This abnormal calcium activity 
is accompanied by premature activation of zymogens 
within pancreatic acinar cells, leading to autodigestion of 
the gland and local inflammation  [2] . Subsequently, neu-
trophils, macrophages, and lymphocytes release pro-in-
flammatory cytokines  [3] such as interleukin-1 (IL-1), IL-
6, IL-8 and tumor necrosis factor-  (TNF  ), generating 
a pronounced systemic inflammatory response with po-
tential subsequent organ failure  [4, 5] .
 As one can expect, several studies aimed at targeting 
specific leukocyte subsets such as neutrophils  [6–9] , lym-
phocytes  [10, 11] , or monocytes  [12–14] and indeed dem-
onstrated a significant improvement of pancreatic dam-
age and mortality in various experimental pancreatitis 
models. However, a clinical translation of these achieve-
ments has yet to take place.
 One of the most interesting pathomechanistic con-
cepts to emerge in recent years was the contribution of
the ‘neurogenic inflammation’ to the generation of acute 
pancreatitis. It has been shown that in acute pancreatitis, 
activated sensory neurons projecting into the pancreas 
can secrete inflammatory neuromediators like substance 
P and bradykinin in an antidromic fashion, leading to 
vasodilatation and increased leukocyte extravasation 
 [15] . Furthermore, inhibition of these sensory neurons 
via antagonists of the transient receptor potential vanil-
loid 1 (TRPV1) channel was shown to significantly re-
duce the severity of caerulein-induced acute pancreatitis 
in mice  [16] .
 Looking at the impressive intersection of the nervous 
system activation and inflammatory cell recruitment in 
the induction of acute pancreatitis, we aimed at investi-
gating the role of a molecule in acute pancreatitis that 
seems to well fit into this intersection:  L -glycine.  L -Gly-
cine is a nonessential amino acid which acts as an inhib-
itory neurotransmitter in the central nervous system and 
mediates a chloride influx and thus neuronal hyper-
polarization via a glycine-gated chloride-sensitive trans-
membrane channel (GlyR)  [17] . However, the critical 
finding that  L -glycine could act as an anti-inflammatory 
agent was based on the expression of GlyR on leukocytes 
including neutrophils, Kupffer cells, and splenic and al-
veolar macrophages  [19] . Activation of the GlyR on these 
cells can, as known for neurons, result in hyperpolariza-
tion of the plasma membrane and hereby blunting in-
creased intracellular calcium concentrations. As a result, 
production of cytokines  [18] and the subsequent inflam-
matory cell activation is inhibited, and the formation of 
free radicals is decreased  [19, 20] . Over these mecha-
nisms, glycine was shown to have a protective effect in 
several experimental disease models such as ischemia-
reperfusion injury  [21, 22] , shock  [23] , liver transplanta-
tion  [24–26] , arthritis  [27] and alcoholic hepatitis  [28] .
 For these reasons, we tested the potential of the neuro-
immune linking molecule glycine as a prophylactic agent 
in two rat models of acute pancreatitis. For this purpose, 
we administered glycine intravenously before induction 
of a mild-edematous (cerulein) or severe-hemorrhagic 
(sodium taurocholate) pancreatitis in rats and examined 
the degree of pancreatic damage, intrapancreatic inflam-
mation and pain under the influence of glycine.
 Material and Methods 
 Pancreatitis Models and Glycine Treatment 
 All animal procedures were performed in accordance with 
ethical guidelines as specified by the local governing body. Male 
Sprague-Dawley rats (200–250 g), obtained from Charles River 
Laboratories, were maintained on a 12-hour light/dark cycle at 22 
 8 2   °   C and relative humidity of 50  8 5%. Animals were fed ad 
libitum on a standard diet and had free access to water. All ani-
mals were anaesthetized by intraperitoneal injection of Narco-
ren  (17 mg/kg BW) and intramuscular injection of Ketanest S  
25 mg (100 mg/kg BW). Mild edematous and necrotizing acute 
pancreatitis were both induced, as described previously  [29] . Se-
vere acute necrotizing pancreatitis was performed by retrograde 
injection of sodium taurocholate (3%) in the common biliopan-
creatic duct with a constant pressure of 30 cm H 2 O/min using an 
infusion pump (Harvard Apparatus, Inc., Holliston, Mass., USA). 
Acute edematous pancreatitis was induced by a continuous infu-
sion of supramaximal concentrations of cerulein (10   g/kg BW/h) 
via a central venous line for 6 h. Ten minutes prior to induction of 
the taurocholate pancreatitis/cerulein pancreatitis or sham treat-
ment, the glycine groups (n = 8) received a single intravenous bo-
lus of 100 or 300 mmol glycine, respectively. The sham groups
(n = 6, each group) received either a retrograde infusion of an 
equivalent volume of NaCl into the common bilio-pancreatic 
duct, or NaCl was given intravenously instead of cerulein. After 
the observation period of 6 h in the cerulein and after 24 h in the 
taurocholate pancreatitis, exsanguination was performed under 
anesthesia, as mentioned above. The pancreas was rapidly re-
moved and trimmed of fat; pancreatic tissue including the head 
and tail were divided into several parts, and the aliquots were fro-
zen in liquid nitrogen and stored at –80  °  C for protein extraction 
and fixed in 5% paraformaldehyde and later embedded in paraf-
fin for histological analysis.
 Histological Examination 
 Paraffin-embedded tissue sections (3   m) were stained with 
hematoxylin and eosin. Histopathological analysis was performed 
by 2 independent observers (F.B., M.K.) blinded to diagnosis and 
treatment, followed by resolution of any differences by joint review 
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and consultation with a third observer (G.O.C.). Histomorpho-
logical evaluation of the specimen included the quantification of 
the morphological severity of the two acute pancreatitis forms ac-
cording to the point score system of Spormann, as previously de-
scribed  [30, 31] . Potential systemic effects of glycine were investi-
gated in the right middle lung lobe. Morphological changes were 
evaluated, and digital imaging was performed with the Zeiss Ax-
ioCam HR system (Carl Zeiss AG, Oberkochen, Germany).
 An observer blinded to glycine treatment performed grading 
of intrapancreatic vacuolization in the cerulein pancreatitis. In 
tissue sections of the pancreatic head and tail, 5 randomly select-
ed areas were photographed, and the total number of vacuoles was 
counted. The mean numbers of the vacuoles in the analyzed 5 ar-
eas were regarded as the representative figure for each animal.
 Trypsin and Elastase Activity in Pancreatic Homogenates 
 Tissue was homogenized on ice in 100 mmol/l Tris (pH 8) and 
5 mmol/l CaCl 2 and centrifuged for 10 min at 20,000  g  at 4   °   C. 
Protein content was determined according to the method of Brad-
ford. 10   mol/l of elastase substrate R110-(CBZ-Ala4)2, 10   mol/l 
of trypsin substrate R110-(CBZ-Ile-Pro-Arg)2, and 1   g protein, 
respectively, were incubated in 150   l final volume at an excita-
tion wavelength of 485 nm and an emission wavelength of 530 nm 
at 37  °  C. Initial rates of substrate hydrolysis were measured in ar-
bitrary fluorescence units per minute. Enzyme activity was cal-
culated as units per milligram with purified elastase and trypsin 
as an internal standard, and activity was set in relation to caeru-
lein- and taurocholate-treated animals, as demonstrated previ-
ously  [32] .
 Measurement of Serum Amylase and Lipase 
 Serum amylase and lipase were detected using the automatic 
chemical analyzer ADVIA2400. The analyses were performed ac-
cording to the IFCC Method (International Federation of Clinical 
Chemistry and Laboratory Medicine).
 Myeloperoxidase Activity in Pancreatic and Lung 
Homogenates 
 Tissue processing was performed as demonstrated recently 
 [32] . Tissue was homogenized on ice in 20 mmol/l potassium phos-
phate buffer (pH 7.4) and centrifuged for 10 min at 20,000  g  at 4  °  C. 
The pellet was resuspended in 50 mmol/l potassium phosphate 
buffer (pH 6.0) containing 0.5% cetyltrimethylammonium bro-
mide. The suspension was frozen/thawed 4 times, sonicated twice 
for 10 s, and centrifuged at 20,000  g  for 10 min at 4  °  C. Myeloper-
oxidase (MPO) activity was assayed after mixing 50   l superna-
tant in 200   l of 50 mmol/l potassium phosphate buffer (pH 6) 
containing 0.53 mmol/l O-dianisidine and 0.15 mmol/l H 2 O 2 . The 
initial increase in absorbance at 460 nm was measured at room 
temperature with a Dynatech MR 5000 Elisa reader (Eningen, 
Germany). The results are expressed in units of MPO activity on 
the basis of 1 unit being able to oxidize 1   mol H 2 O 2 per minute 
per milligram pancreatic protein. Bars indicate mean values in 
mU MPO activity/mg pancreatic protein  8 SEM per time point.
 ELISA Analysis of IL-1, IL-6, IL-10 and TNF  in Pancreatic 
Homogenates 
 For ELISA-analysis, pancreatic homogenates were processed 
as described previously  [33] . IL-1, IL-6 and IL-10 and TNF  levels 
were quantified using specific rat ELISA kits obtained by R&D 
Biotechniques (DY501, DY506, DY522, DY510). ELISA analyses 
were performed according to the manufacturers’ instructions 
(R&D Biotechniques).
 Behavioral Pain Testing 
 Behavioral measurements were carried out in awake, unre-
strained rats in a blinded manner using the standardized open-
field test  [34] . Behavioral activity was measured for periods of
5 min before the induction of pancreatitis, 12 and 24 h after tau-
rocholate and 6 h after caerulein pancreatitis. The behavior was 
analyzed for urination, feces, straighten up (vertical activity), 
crossing the lines (inner rows) and cleaning. The open-field ap-
paratus was a square wooden box (70  ! 70  ! 60 cm), painted 
white. The floor was divided into 16 equal-sized squares (17.5  ! 
17.5 cm). Each activity chamber was cleaned with alcohol between 
tests to eliminate urine and olfactory cues from previous subjects.
 Statistical Analysis 
 Statistical analysis was performed using the GraphPad Prism 
4 Software. The Shapiro-Wilk test was used to evaluate data dis-
tribution. Results are expressed as mean  8 SEM. Comparisons of 
histological changes, MPO activity, tissue homogenate analysis 
and behavioral testing were performed using analysis of variance 
for random measures followed by Bonferroni’s post hoc test. Two-
sided p values were always computed, and an effect was consid-
ered statistically significant at p  ^  0.05.
 Results 
 Glycine Improves Pathomorphological Changes in 
Experimental Pancreatitis 
 Cerulein Pancreatitis 
 In rats with cerulein pancreatitis, all typical changes 
with immense inter- and intralobular edema, immune 
cell infiltration and cytoplasmatic vacuoles in the acini 
were evident ( fig. 1 a, b). Treatment with 100 mmol (2.3  8 
0.3; p  ! 0.001) and 300 mmol (3.0  8 0.2; p  ! 0.01) glycine 
resulted in a remarkable reduction of the entire pancre-
atic damage (Spormann score) compared to nontreated 
animals (4.2  8 0.2) ( fig. 1 a–g). In detail, compared to the 
cerulein animals (2.2  8 0.1) the inflammatory cell infil-
tration was markedly reduced in the 100 mol glycine-
treated animals (1.2  8 0.2; p  ! 0.01) and also tended to 
decrease at higher concentrations of glycine (300 mmol, 
1.7  8 0.2) but failed to reach statistical significance 
( fig. 1 h). Furthermore, pretreatment with 100 mmol (1.3 
 8 0.2; p  ! 0.05) and 300 mmol (1.3  8 0.1; p  ! 0.001) gly-
cine noticeably reduced pancreatic edema compared to 
nontreated animals (1.9  8 0.1) ( fig. 1 a–f, i). All cerulein 
pancreatitis animals with or without glycine treatment 
did not show up any fat or parenchymal necrosis. Both 
sham groups did not show any pathomorphological 
changes in the pancreas at all.
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 The cytoplasmatic vacuoles, regarded as one the major 
characteristic changes of cerulein-induced pancreatitis, 
were markedly diminished by glycine pretreatment at the 
concentrations of 100 mmol (84  8 13; p  ! 0.01) and 300 
mmol (70  8 11; p  ! 0.001), compared to nontreated ani-
mals (151  8 6) ( fig. 2 a–d).
 Taurocholate Pancreatitis 
 The untreated taurocholate animals showed severe 
pathomorphological changes (8.9  8 0.7), including ede-
ma, massive immune cell infiltration, hemorrhage and 
aggravated fat and parenchymal necrosis ( fig. 3 a, b). This 
severe pancreatic damage was impressively reduced by 
Cerulein Cerulein/glycine 100 Cerulein/glycine 300
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b
c
d
e
f
 Fig. 1. Representative pictures demonstrating the effect of 100 
mmol/Cer 100 ( c ,  d ) and 300 mmol/Cer 300 ( e ,  f ) glycine pretreat-
ment on the course of cerulein pancreatitis/Cer.  a ,  b Representa-
tive areas of damaged pancreatic parenchyma without glycine 
treatment. Glycine treatment improved pathomorphological 
changes in cerulein pancreatitis and noticeable reduced the Spor-
mann score in the pretreated animals ( g ). Especially inflamma-
tion ( h ) and edema ( i ) were significantly attenuated in glycine- 
pretreated animals. Sham: NaCl is given intravenously instead
of cerulein; shamG: NaCl is given intravenously instead of ce-
rulein + 300 mmol glycine. Data are presented as mean  8 SEM. 
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glycine pretreatment with 100 mmol (4.1  8 0.9) and 300 
mmol (5.2  8 1.0) ( fig. 3 g). Fat (1.8  8 0.3) and parenchy-
mal necrosis (2.0  8 0.3) significantly decreased under 
300 mmol glycine treatment (0.5  8 0.2/0.6  8 0.3; p  ! 
0.05) ( fig. 3 h, i). Pancreatic edema was attenuated with 
glycine treatment only at lower concentrations with 100 
mmol (1.0  8 0.01; p  ! 0.05) compared to taurocholate-
only treated animals (2.0  8 0.3) ( fig. 3 i). Both the sever-
ity of inflammatory cell infiltration and hemorrhage 
tended to be decreased with glycine pretreatment not 
reaching statistical significance (data not shown).
 Animals with taurocholate-pancreatitis developed a 
significantly higher amount of ascites (12  8 3 ml), where-
as the animals with 100 mmol glycine pretreatment had 
nearly no ascites production at all (0.02  8 0.01 ml; p  ! 
0.01;  fig. 3 k). Treatment with glycine at a dosage of 300 
mmol (2.6  8 1.7 ml; p  ! 0.05) noticeably decreased asci-
tes development during the course of acute necrotizing 
pancreatitis ( fig. 3 k).
 Effect of Glycine on Pancreatitis-Specific Biomarkers 
 To study whether glycine pretreatment is affecting 
specific biomarkers for pancreatitis, serum lipase and 
amylase were determined. In the edematous cerulein 
pancreatitis, glycine treatment did not change serum lev-
els for lipase or amylase ( fig. 4 a, b). In contrast, glycine 
application in animals prior to induction of severe necro-
tizing taurocholate pancreatitis noticeably reduced both 
lipase and amylase in a significant manner. Animals 
treated with 100 mmol (22  8 9 U/l; p  ! 0.01) or 300 mmol 
(52  8 22 U/l; p  ! 0.01) glycine revealed noticeable re-
duced lipase values when compared to non-treated ani-
mals (295  8 130 U/l) ( fig. 4 c). In a similar way also amy-
lase levels were significantly reduced by glycine treatment 
(100 mmol: 2,580  8 775 U/l, p  ! 0.05; 300 mmol: 3,239 
 8 525 U/l, p  ! 0.05) compared to taurocholate animals 
(7,904  8 2,195 U/l) ( fig. 4 d).
 Glycine and Intrapancreatic Activation of Trypsin and 
Elastase during Experimental Pancreatitis 
 In order to investigate if glycine pretreatment is affect-
ing premature activation of pancreatic zymogens, we 
measured the activity of trypsin and elastase in pancre-
atic homogenates. Different concentrations of glycine did 
not alter intrapancreatic activation of trypsin and elas-
tase neither in the mild cerulein nor in the severe tauro-
cholate pancreatitis (data not shown). Trypsin activity 
tended to be attenuated by glycine pretreatment in the 
taurocholate pancreatitis but failed to reach statistical 
significance.
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 Fig. 2. Representative pictures of acinar cytoplasmatic vacuoles in cerulein pancreati-
tis ( a ) and after pretreatment with 100 mmol ( b ) or 300 mmol glycine ( c ). Glycine 
pretreatment markedly reduced the acinar cytoplasmatic vacuoles ( d ). Data are pre-
sented as mean  8 SEM.  a–c  ! 100. 
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Taurocholate Taurocholate/glycine 100 Taurocholate/glycine 300
a
b
c
d
e
f
 Fig. 3. Representative pictures demonstrating the effect of 100 
mmol/Tau 100 ( c ,  d ) and 300 mmol/Tau 300 ( e ,  f ) glycine pretreat-
ment on the course of severe taurocholate (3%) pancreatitis/Tau.  a , 
 b Areas of damaged pancreatic parenchyma without glycine treat-
ment. Glycine treatment improved pathomorphological changes in 
taurocholate pancreatitis and noticeably reduced the Spormann 
score in the pretreated animals ( g ). Especially fat ( h ) and paren-
chyma ( i ), necrosis and edema ( j ) were significantly attenuated in 
glycine-pretreated animals. The amount of reactive ascites produc-
tion was diminished by glycine pretreatment ( k ). Sham: retrograde 
infusion of an equivalent volume of NaCl into the common bilio-
pancreatic duct. Data are presented as mean  8 SEM.  a–f  ! 100. 
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 Influence of Glycine on Leukocyte Transmigration 
into the Pancreas and Lung during Experimental 
Pancreatitis 
 To study whether tissue leukocyte infiltration is influ-
enced by glycine pretreatment, we measured the myelo-
peroxidase (MPO) activity in pancreatic and lung tissue 
homogenates. The pancreatic MPO activity was not af-
fected by glycine pretreatment in mild cerulein-induced 
pancreatitis, whereas in taurocholate-induced pancreati-
tis (300  8 76), glycine treatment with 100 mmol (83  8 
20; p  ! 0.01) and 300 mmol (126  8 30; p  ! 0.05) mark-
edly reduced the pancreatic MPO activity ( fig. 5 a, b). Gly-
cine pretreatment had no impact on the MPO activity in 
the lungs during severe taurocholate acute necrotizing 
pancreatitis ( fig. 5 c).
 Glycine Ameliorates Pancreatic Cytokine Activation in 
Experimental Pancreatitis 
 To study whether glycine pretreatment can interfere in 
the release of the pro-inflammatory cytokines during the 
course of acute pancreatitis, IL-1, IL-6, TNF  and the 
anti-inflammatory cytokine IL-10 were measured via 
ELISA in pancreatic homogenates. In mild cerulein pan-
creatitis, none of the investigated cytokines were affected 
by glycine treatment (data not shown). But again in the 
severe taurocholate pancreatitis, the release of IL-1 and 
TNF  within the damaged pancreatic tissue was mark-
edly reduced compared to the sham animals without gly-
cine treatment ( fig. 6 a, c). IL-6 tended to be diminished 
in animals with glycine pretreatment, but this finding did 
not reach statistical significance ( fig.  6 b). Interestingly, 
also IL-10 was significantly reduced in the glycine-pre-
treated groups ( fig. 6 d).
 Glycine Has No Impact on Pancreatic Pain Sensation 
in Acute Pancreatitis 
 Glycine receptors are currently considered to be new 
targets for pain therapies  [35] . As abdominal pain repre-
sents the most common symptom in patients with acute 
necrotizing pancreatitis, potential effects of glycine pre-
treatment on analgesia were investigated in a standardized 
open-field test. The behavior was analyzed for ‘straighten 
up’ (vertical activity), ‘crossing the lines’ (inner rows) and 
‘cleaning’ (horizontal activity) during the course of tauro-
cholate pancreatitis at the time points 0, 12 and 24 h. In 
none of the time points did pretreatment with 100 or 300 
mmol glycine have an analgesic effect on the taurocholate 
pancreatitis animals. Vertical activity tented to be increased 
in animals treated with 300 mmol glycine, but the results 
did not reach statistical significance (data not shown).
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 Fig. 4. Effect of glycine on serum pancre-
atitis markers. Glycine pretreatment did 
not influence lipase ( a ) and amylase levels 
( b ) during the course of cerulein pancre-
atitis. In taurocholate pancreatitis, lipase 
( c ) as well as amylase levels ( d ) were notice-
ably attenuated after 24 h of taurocholate 
pancreatitis. Data are presented as mean 
 8 SEM. 
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 Discussion 
 To analyze the potential therapeutic impact of glycine 
on the course of acute pancreatitis, the cerulein-induced 
mild and the taurocholate-induced severe models of pan-
creatitis were chosen. Here, we could demonstrate that gly-
cine significantly attenuated pancreatic tissue damage in 
acute pancreatitis when given prophylactically. Especially 
in severe taurocholate pancreatitis, glycine reduced pan-
creatic enzymes, cytokine production and MPO activity.
 Considering the current knowledge on the pathophys-
iology of acute pancreatitis, there seems to be several 
point of action, which explains the protective effects of 
glycine in acute pancreatitis. First, as abnormal calcium 
influx is a crucial event in acute pancreatitis leading to 
premature zymogen activation, glycine might act via the 
glycine-gated chloride channels and cause a hyperpolar-
ization of the acinar plasma membrane  [36] . As a result, 
the opening of the voltage-gated calcium channels and a 
subsequent increase of intracellular calcium concentra-
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tion would be prevented and hereby premature zymogen 
activation  [37] . In this regard, our results showing de-
creased vacuole formation (which contain trypsinogen 
and cathepsin B) in the glycine pretreatment group seem 
to confirm this mechanism.
 Another possibility is the stabilization of the acinar 
membrane by glycine. During acute pancreatitis, the con-
version of trypsinogen into active trypsin within acinar 
cells is followed by an activation of several enzymes, such 
as elastase, phospholipase A 2 and NADPH oxidase  [38] . 
Through the increase of intracellular calcium concentra-
tion, elastase and ROS (H 2 O 2 ), NADPH oxidase and phos-
pholipase A 2 are activated  [39, 40] . Here, it should be con-
sidered that glycine inhibits phospholipase A 2 , an event 
which leads to stabilization of the cell membrane  [41] . As 
a result, the cell is less sensitive towards oxidative stress 
and radicals, which usually result in apoptosis and necrot-
ic cell death. In accordance with this notion, we observed 
less parenchymal and fat tissue necrosis in the glycine-
pretreated groups when compared to the control groups.
 In addition to its potential direct protective effects on 
acinar cells, a major site of action for glycine would be the 
systemic inflammatory response. In acute pancreatitis, a 
striking inflammatory response and an activation of oth-
er inflammatory cascades like the kinin and complement 
pathways follows premature activation of enzymes  [42] . 
Furthermore, the activation of the above-mentioned oxi-
dizing enzymes increases the amount of oxygen radicals 
and thus oxidative stress. A glycine-mediated protection 
from oxidative stress was not observed on hepatocytes 
 [43] . Nevertheless, the damage mediated by oxygen radi-
cals results in increased NF-  B expression  [44] . Subse-
quently, NF-  B activates the proinflammatory cytokine 
production within the pancreas, including the produc-
tion of the TNF   [45] , Il-6  [46] and IL-1   [47] , platelet 
activating factor and leukotriene B 4  [48] which lead to 
enhanced recruitment of neutrophils, macrophages, and 
lymphocytes to the site of inflammation. These cells fur-
ther produce cytokines like IL-1, IL-6, and IL-8  [49] . 
Since the glycine receptor GlyR is expressed on inflam-
matory cells  [50] , these cells might be another possible 
spot for glycine interference. In this context, glycine may 
be exerting an inhibitory action on these inflammatory 
cells as it otherwise does on neurons, or it may be render-
ing the leukocytes less sensitive to inflammatory stimuli, 
as previously shown for glycine-mediated endotoxin de-
sensitization  [51, 52] . In our study, we could show less in-
flammation and also decreased interleukin levels in the 
glycine pretreatment groups, e.g., IL-1 and TNF  were 
significantly decreased in severe pancreatitis. Interest-
ingly, this inhibitory effect upon leukocyte activity and 
sequestration was mainly present within the pancreas but 
not in the lungs, as evidenced by the differences in the 
MPO activity of the control and pretreatment groups. 
The accompanying decrease in the anti-inflammatory 
cytokine IL-10 level is a finding in support of this protec-
tive effect of glycine since IL-10 is known to be increased 
in experimental acute pancreatitis in parallel with TNF  
production  [53] . However, the absence of any alterations 
in the pancreatic enzyme activation and the reduction of 
pro-inflammatory cytokines after glycine pretreatment 
strongly suggests that glycine is predominantly inhibi-
tory on the systemic inflammatory response but not on 
the local damage in the pancreas. This specific action of 
glycine upon systemic but not local inflammation is not 
genuinely specific for glycine. In a previous study, it was 
demonstrated that also other agents, i.e. statins, also re-
duce systemic inflammatory cytokines but not pancre-
atic vascular permeability, tissue water content, histolog-
ical lesions in the pancreas. This differential responsive-
ness of these two arms of mechanisms implies that 
combination therapies targeting at both the pancreatic 
and systemic inflammation may be more beneficial than 
therapies targeting either of the two.
 At this point, it is difficult to explain why glycine ex-
erted a more prominent inhibitory effect in the more se-
vere form of taurocholate pancreatitis. The more promi-
nent inhibition of cytokine production might be due to 
the fact that severe forms of pancreatitis are associated 
with a naturally higher degree of inflammatory cell re-
cruitment. Indeed, neutrophils, as cytokine-secreting
inflammatory cells, have been shown to determine the 
severity of the injury to the gland as well as the distant 
organs. Furthermore, a comparison of these models pre-
viously revealed that these two models are characterized 
by differences in origin and evolution of tissue injury. For 
example, in taurocholate pancreatitis, oxygen radicals 
produced by xanthine oxidase activity were shown to be 
probably induced by cell death, whereas in cerulein pan-
creatitis, other sources of oxygen free radicals, such as 
inflammatory cells, were considered to be more likely 
 [54] . Overall, it is plausible that these two models may be 
marked by two different patterns of generation of inflam-
mation and thus by different glycine responsiveness.
 The lack of an analgesic effect for glycine in our study 
should not restrain researchers from studying its possibly 
analgesic effects in pancreatitis. In fact, most studies in 
the literature aiming at modulating glycine activity or its 
receptor involve chronic or neuropathic rather than acute 
pain conditions as seen in acute pancreatitis  [55] . Hence, 
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 In summary, this study shows for the first time the 
protective effect of amino acid glycine in both mild and 
severe experimental acute pancreatitis. It seems that gly-
cine can exert its anti-inflammatory, cytoprotective ac-
tion via several mechanisms, through pancreatic acinar 
membrane stabilization, via its direct inhibitory effect on 
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